EDUCATIONAL NOTICE: Peptidings provides information for educational and research purposes only. The compounds discussed on this page are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.

Browse by Condition

Athletic Recovery

Athletic recovery draws from more peptide clusters than any other condition on Peptidings—direct tissue repair compounds, muscle-specific growth factors, myostatin inhibitors, growth hormone secretagogues, and sleep regulators. What unites them is the question: can exogenous peptides accelerate the body’s recovery from training stress, injury, and competitive demands?

WADA status matters more here than in any other condition. Athletes considering these compounds need to know not only whether they work, but whether they are permitted in competition. Several compounds on this page are explicitly prohibited in sport, and the gap between community use and published human evidence is wider than in any other category on the site.

Condition at a Glance

16

Compounds Researched

1

FDA Approved

2

Clinical Trials

9

Pilot Data

4

Preclinical

Approved Drug

FDA-approved or equivalent regulatory approval

Clinical Trials

Human clinical trial data (Phase I+)

Pilot / Limited Human Data

Small or preliminary human studies

Preclinical Only

Animal models and cell culture only

BLUF: Bottom Line Up Front

BPC-157 and TB-500 are the community favorites—extensive rodent data for tissue repair, minimal controlled human data for sports injuries. The Cluster N muscle signals (IGF-1 LR3, IGF-1 DES, MGF, Follistatin) are preclinical in the context of athletic recovery—they work in rodent models but lack human performance data, and several are unambiguously WADA-prohibited. The GH secretagogues (Sermorelin, MK-677, Ipamorelin, CJC-1295, GHRP-2/6, Hexarelin) affect recovery indirectly through growth hormone elevation—real mechanism, but they are not tissue-repair compounds. Sermorelin is the only FDA-approved entry, and its approval was historical (1997) and later withdrawn from the U.S. market. DSIP addresses sleep, which is arguably the most important recovery lever of all.

Compounds Researched for This Condition

16 compounds with published research relevant to athletic recovery. Evidence tiers reflect the strength of research for this specific condition—not the compound’s highest overall tier.

Group 1 of 4

The Direct Tissue Repair Peptides

Compounds with direct mechanisms for accelerating tissue healing—the core of peptide-based athletic recovery.

3Pilot / Limited Human Data WADA

BPC-157

Gastric pentadecapeptide. 100+ rodent studies across tendon, ligament, muscle, bone, and gut healing. The most-studied preclinical repair peptide on earth. Fewer than 6 small, uncontrolled human studies.

Read the Full Article →

3Pilot / Limited Human Data WADA

TB-500

Synthetic fragment of Thymosin Beta-4. Promotes cell migration and angiogenesis. Widely used in veterinary medicine (racehorses). Minimal human clinical data for sports injuries.

Read the Full Article →

3Pilot / Limited Human Data

Thymosin Beta-4

Full 44-amino-acid actin-binding protein. The parent molecule of TB-500. Clinical trials have explored cardiac, corneal, and wound-healing applications. Separate evidence stream from TB-500.

Read the Full Article →

3Pilot / Limited Human Data

GHK-Cu

Copper tripeptide with wound healing, collagen remodeling, and anti-inflammatory effects. The most biologically versatile compound in this group. Both topical and injectable evidence exists.

Read the Full Article →

Group 2 of 4

The Muscle Growth & Repair Signals

Growth factors and inhibitors that target muscle tissue directly—driving hypertrophy, repair, and anabolic signaling at the myocyte level. All WADA-prohibited in sport.

4Preclinical Only WADA

IGF-1 LR3

Modified IGF-1 with extended half-life (~20 hours vs. minutes for native IGF-1). Anabolic muscle growth signaling. Widely used in bodybuilding communities. Zero controlled human trials for athletic performance or recovery.

Read the Full Article →

4Preclinical Only WADA

IGF-1 DES

Truncated IGF-1 variant with selective local tissue action. Theoretically allows site-specific muscle growth. Preclinical data only. No published human performance data.

Read the Full Article →

4Preclinical Only WADA

MGF / PEG-MGF

Mechano growth factor—an IGF-1 splice variant upregulated during muscle loading. Activates satellite cell proliferation in rodent models. PEGylation extends half-life. No human performance data.

Read the Full Article →

4Preclinical Only WADA

Follistatin

Myostatin inhibitor. Blocking myostatin increases muscle mass dramatically in animal models. Gene therapy trials exist for Duchenne muscular dystrophy. Recombinant follistatin is not a tested human performance therapy.

Read the Full Article →

Group 3 of 4

The GH Secretagogues

Compounds that elevate endogenous growth hormone—supporting recovery indirectly through GH's effects on protein synthesis, tissue repair, and sleep quality.

1Approved Drug WADA

Sermorelin

GHRH(1-29) analogue. FDA-approved (historically) for GH deficiency. Stimulates pulsatile GH release. Market withdrawn but still used clinically via compounding. The most physiological GH secretagogue.

Read the Full Article →

2Clinical Trials WADA

MK-677 (Ibutamoren)

Oral GH secretagogue (not a peptide). Multiple Phase 2 RCTs showing sustained GH and IGF-1 elevation. Improves sleep quality—relevant to recovery. Does not directly repair tissue.

Read the Full Article →

2Clinical Trials WADA

Ipamorelin

Selective ghrelin mimetic GH secretagogue. Cleaner release profile than GHRP-6 (less hunger, less cortisol). Phase 2 data exists. Often combined with CJC-1295.

Read the Full Article →

3Pilot / Limited Human Data WADA

CJC-1295 (no DAC)

Modified GHRH analogue. Elevates GH in a pulsatile, physiological pattern. Often paired with Ipamorelin. Limited human data as a standalone compound for recovery.

Read the Full Article →

3Pilot / Limited Human Data WADA

GHRP-2

First-generation ghrelin mimetic. Pilot data for GH elevation in adults. Increases appetite and cortisol alongside GH. Older compound largely superseded by Ipamorelin in clinical use.

Read the Full Article →

3Pilot / Limited Human Data WADA

GHRP-6

Early-generation GH secretagogue. Potent GH release coupled with pronounced appetite stimulation. Used occasionally in cachexia research. Not a recovery-specific compound.

Read the Full Article →

3Pilot / Limited Human Data WADA

Hexarelin

Potent GH secretagogue with observed cardioprotective effects in animal models. Strong GH response but rapid receptor desensitization limits long-term use. Limited clinical development.

Read the Full Article →

Group 4 of 4

The Sleep Recovery Compound

One peptide researched specifically for its role in sleep regulation—the single most important recovery mechanism.

3Pilot / Limited Human Data

DSIP

Delta sleep-inducing peptide. Originally isolated for its ability to modulate slow-wave sleep. Limited clinical data, mostly Soviet-era. Sleep quality is the foundation of athletic recovery—DSIP's relevance is indirect but mechanistically sound.

Read the Full Article →


What the Research Landscape Looks Like

Athletic recovery compounds work through four fundamentally different pathways. The direct tissue repair peptides (BPC-157, TB-500, Thymosin Beta-4, GHK-Cu) aim to accelerate healing at the injury site through angiogenesis, cell migration, collagen remodeling, and inflammatory modulation. The muscle growth signals (IGF-1 LR3, IGF-1 DES, MGF, Follistatin) target the myocyte directly—driving anabolic signaling and, in the case of Follistatin, removing the natural brake on muscle growth. The GH secretagogues (Sermorelin, MK-677, CJC-1295, Ipamorelin, GHRP-2/6, Hexarelin) work indirectly—elevating growth hormone, which supports protein synthesis and tissue turnover systemically. DSIP addresses the fourth lever: sleep.

The distinction matters because athletes and coaches often conflate these categories. A GH secretagogue does not ‘heal’ a torn tendon the way BPC-157 aims to. IGF-1 LR3 does not repair a ligament—it drives muscle hypertrophy. And BPC-157’s 100+ rodent studies do not include a single controlled human trial for sports injuries. The gap between community use and published evidence is widest in this condition. Nearly every compound on this page is WADA-prohibited in sport—the one exception on the broader recovery landscape (Thymosin Beta-4) has more ambiguous status and is treated conservatively here.

Mechanism Compounds
Direct Tissue Repair
Accelerating healing at the cellular level—angiogenesis, cell migration, collagen synthesis, and extracellular matrix remodeling.
BPC-157, TB-500, Thymosin Beta-4, GHK-Cu
Muscle Anabolic Signaling
Driving protein synthesis and hypertrophy through IGF-1 pathway activation and satellite cell proliferation at the muscle fiber level.
IGF-1 LR3, IGF-1 DES, MGF / PEG-MGF
Myostatin Inhibition
Blocking myostatin, the body's natural brake on muscle growth—removing an endogenous ceiling on hypertrophy.
Follistatin
Growth Hormone Elevation
Stimulating endogenous GH release to support systemic recovery—protein synthesis, fat metabolism, and sleep quality.
Sermorelin, MK-677, CJC-1295, Ipamorelin, GHRP-2, GHRP-6, Hexarelin
Sleep Regulation
Modulating sleep architecture to enhance slow-wave sleep—the recovery phase during which most tissue repair occurs.
DSIP

Plain English

Four approaches to recovery on this page: (1) fix the injury directly—BPC-157, TB-500, Thymosin Beta-4, GHK-Cu try to speed up healing at the tissue level; (2) grow the muscle directly—IGF-1 LR3, IGF-1 DES, MGF drive muscle protein synthesis, and Follistatin removes the brake on muscle growth; (3) support the whole system—GH secretagogues like MK-677, Ipamorelin, CJC-1295, and GHRP-2/6 boost growth hormone, which helps recovery broadly; (4) fix sleep—DSIP is researched for slow-wave sleep. The muscle growth compounds have the least human data—most of that category is preclinical. Nearly everything on this page is WADA-prohibited. Athletes need to check status before considering any of this.

Stay Current

New research, new articles, no noise

Peptidings publishes long-form peptide research articles grounded in primary literature. Subscribe to get new compound articles, cluster updates, and evidence reviews delivered to your inbox.

Subscribe on Substack

Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed are subjects of ongoing scientific research and have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.

Scroll to Top